[新诊断的D2期前列腺癌患者单纯激素治疗与联合顺铂和甲氨蝶呤化疗的比较]
[Comparison of hormone therapy alone and in combination with chemotherapy of cisplatin and methotrexate in newly diagnosed patients with stage D2 prostatic cancer].
作者信息
Komatus H, Maesawa H, Tanabe N, Tago K, Ueno A
机构信息
Department of Urology, Yamanashi Medical University, Japan.
出版信息
Nihon Hinyokika Gakkai Zasshi. 1996 Apr;87(4):789-96. doi: 10.5980/jpnjurol1989.87.789.
BACKGROUND
Prognosis of hormone-refractory prostatic cancer is dismal. We evaluated the efficacy of cytotoxic chemotherapy in combination with hormone therapy in patients with newly diagnosed metastatic prostatic cancer.
METHODS
From February 1984 to March 1992, 39 newly diagnosed patients with stage D2 prostatic cancer were randomized to orchiectomy plus diethylistilbestrol diphosphate or orchiectomy plus diethylstilbestrol diphosphate plus combination chemotherapy with cisplatin and methotrexate.
RESULTS
There was not significant difference in survival or progression-free survival between the two groups.
CONCLUSION
Chemotherapy has not been proved to prolong survival or progression-free survival in patients who received hormone therapy.
背景
激素难治性前列腺癌的预后很差。我们评估了细胞毒性化疗联合激素疗法对新诊断的转移性前列腺癌患者的疗效。
方法
1984年2月至1992年3月，39例新诊断的D2期前列腺癌患者被随机分为睾丸切除术加己烯雌酚二磷酸酯组或睾丸切除术加己烯雌酚二磷酸酯联合顺铂和甲氨蝶呤化疗组。
结果
两组患者的生存率或无进展生存率无显著差异。
结论
对于接受激素疗法的患者，化疗尚未被证明能延长生存期或无进展生存期。
Zotero 插件